You know how GLP-1s impact diabetes and weight loss. But what about coronary disease treatment and prevention? Liver disease? Heart failure? Osteoarthritis? Sleep apnea? In this special episode, Dr. Neil Skolnik covers it all, exploring what we do—and do not—know about the expanding scope of GLP-1-based therapies.
This special episode is sponsored with support from Lilly.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Donna Ryan, MD, professor emeritus at the Pennington Biomedical Research Center in Baton Rouge, Louisiana and former president of both the Obesity Society and the World Obesity Federation
References:
The expanding landscape of GLP-1 medicines. Nature Medicine volume 32, pages 47–57 (2026) doi.org/10.1038/s41591-025-04124-5
Weight-loss-independent actions of GLP-1 medicines. Cell Metabolism, 38, 1535-1539 doi.org/10.1016/j.cmet.2026.07.006
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232 doi.org/10.1056/NEJMoa2307563
Leave a Reply